bpc-157-ship-us BPC-157/TB-500 BPC-157 - Shell Medical

Cadre de recherche

Disclosure of interest: Regina Royan, MD, MPH: Nothing to disclose

You're committing to it

In the development of the GLP-1 receptor agonist, semaglutide, the strategy used to extend the drugs half-life was to promote covalent and non-covalent binding of semaglutide to albumin through the addition of a fatty-acid attachment on semaglutide

By bypassing the digestive system, this method allows for higher levels of vitamin C to reach the bloodstream much more efficiently than through oral supplements

BPC-157, in particular, has been the focus of research involving tissue regeneration and angiogenesis - both essential for supporting recovery in strained or damaged areas